Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicament for the Treatment of Pain and Inflammation

a technology applied in the field of medicine for the relief of pain and inflammation, can solve the problems of difficult treatment, poor response to standard pain treatment, and neuropathic pain, and achieve the effects of convenient and safe treatment, minimal risk of undesirable side effects, and minimal risk of side effects

Inactive Publication Date: 2011-11-10
ANZAMED INT +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a medicament for the transdermal treatment of neurogenic inflammation and neuropathic pain (including peripheral neuropathic pain) that is convenient, safe, and effective with minimal risk of side-effects. The medicament includes vitamin D3 dispersed or dissolved in a carrier medium suitable for transdermal application, such as aqueous-based creams, massage oils, ointments, gels, pessaries / suppositories, patches, and impregnated bandages or other sheet material. The preferred concentration of vitamin D3 in the medicament is in the range 5000 IU / gram to 100,000 IU / gram. The medicament is applied by transdermal application to provide pain relief. The invention is based on the discovery that people with persistent, non-specific musculoskeletal pain syndromes resistant to normal forms of treatment have a deficiency of vitamin D3 and can benefit from a vitamin D3 supplement. The invention provides an effective treatment for neurogenic inflammation and neuropathic pain that is convenient and safe.

Problems solved by technology

Neurogenic inflammation, and the resulting neuropathic pain, typically are difficult to treat and often respond poorly to standard pain treatments.
Treatments typically used for neurogenic inflammation and neuropathic pain (including peripheral neuropathic pain) include non-steroidal anti-inflammatory drugs, painkillers, anticonvulsant drugs, antidepressant drugs, electrical nerve stimulation, and corticosteroid / local anaesthetic injections; however, none of these treatments reliably reduces the pain in a majority of cases, and in addition may have undesirable side-effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for the Treatment of Pain and Inflammation
  • Medicament for the Treatment of Pain and Inflammation
  • Medicament for the Treatment of Pain and Inflammation

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0022]Patient 1—History: MM, age 46, female, elite masters middle distance runner with 2-month history of right inferior heel pain treated initially with subcutaneous prolotherapy, complicated by infection, complaining of inability to run, difficulty walking, and pain at rest. Past history of bilateral peripatellar pain treated with failed surgical decompression, Achillodynia.

[0023]The patient applied the cream by massaging the cream into the painful area twice a day and after any activity, with the massaging followed by the application of heat where possible. This procedure was followed until all pain and tenderness had disappeared from the area. The treatment was continued for three months, and an assessment of pain was recorded every seven days, as shown in FIG. 1. Over this period, the pain reduced from a severe pain to very little pain, with the pattern of pain reduction being a period of steady decrease of pain followed by a plateau, then a further steady decrease followed by ...

example 2

[0024]Patient 2—History: JF, age 24, female, fitness trainer with 8-month history of left inferior heel pain, complaining of inability to run, difficulty walking, affecting work. Has prior treatment with physiotherapy and podiatry without effect. Past history of bilateral Osgood Schlatter Disease, right medial shin splints and peripatellar pain.

[0025]The patient applied the cream by massaging the cream into the painful area twice a day and after any activity, with the massaging followed by the application of heat where possible. This procedure was followed until all pain and tenderness had disappeared from the area. The treatment was continued for two months:—as shown in FIG. 2, over this period the pain steadily diminished from severe pain to no pain. This patient is still using the cream, and continues to run with no pain.

[0026]The patients from Examples 1 and 2 were monitored for serum vitamin D levels at the end of treatment; both showed normal levels.

example 3

[0027]A total of 14 patients, all suffering from recalcitrant inferior heel pain (plantar fasciitis) were studied over a period of several months. The patients consisted of three males with a mean age of 56 (range 50 to 60) and 11 females with a mean age of 44 (range 23 to 61).

[0028]Inferior heel pain (plantar fasciitis) is a difficult to treat condition, causing high levels of pain and disability for up to four years in one prospective study of 100 patients (BMJ Clinical Evidence Concise June 2006)

[0029]The underlying cause of inferior heel pain is postulated to be due to chronic neurogenic inflammation of the distal Tibial nerves branches known as the medial cutaneous calcaneal nerves.

[0030]All patients in this study had received prior treatment including physiotherapy, cortison injections and podiatry with taping and orthotics without benefit.

[0031]The patients were treated with a cream consisting of a known cream base of a type suitable for transdermal applications of medication...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
compositionaaaaaaaaaa
fat solubleaaaaaaaaaa
Login to View More

Abstract

The use of vitamin D3 for the manufacture of a medicament for the transdermal treatment of neurogenic inflammation and neuropathic pain (including peripheral neuropathic pain); also a method for the relief of neurogenic inflammation and neuropathic pain using this medicament.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a medicament for the relief of pain and inflammation, in particular neurogenic inflammation and neuropathic pain. The medicament of the present invention has been found to be especially effective in the relief of peripheral neuropathic pain.BACKGROUND OF THE INVENTION[0002]Neurogenic inflammation is inflammation of the nerves which is actually caused by the nerves, in the sense that it is caused by the pro-inflammatory neuropeptides released by the nerves when the nerves are irritated, damaged, or injured. The neurogenic inflammation causes the neuropathic pain. Peripheral neuropathic pain is neuropathic pain experienced in the distribution of the peripheral nervous system, i.e. outside the central nervous system (brain and spinal cord). Typical sites for peripheral neuropathic pain are the heels / hands / feet / elbows / knees.[0003]Neurogenic inflammation, and the resulting neuropathic pain, typically are difficult to treat and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/70A61P25/00A61P31/00C07C401/00A61K31/59
CPCA61K31/593A61K9/0014A61P25/00A61P25/02A61P31/00
Inventor LYFTOGT, JAN ANNE
Owner ANZAMED INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com